FBXL20在喉癌组织中的表达

Expression of FBXL20 in Laryngocarcinoma

目的研究FBXL20在喉癌组织中的表达,分析其在喉癌组织和癌旁组织中表达是否有差异,并分析FBXL20表达强度与喉癌临床病理特征:分化程度,有无淋巴结转移,性别,年龄之间的关系及研究与喉癌发生、发展、转移的关系,从而探索在临床应用上的潜在价值。方法采用免疫组化检测30例喉癌组织和癌旁组织中FBXL20的表达情况。结果 FBXL20在正常组织和肿瘤组织均有表达,其多集中于胞浆中,FBXL20在正常组织中阳性表达率较高于肿瘤组织,FBXL20在正常组织中的表达与肿瘤组织相比,差异有统计学意义(P=0.004),其表达在有无侵犯淋巴结中差异有统计学意义(P=0.044),与性别,年龄和分化程度无关。结论 FBXL20可能在喉癌的发生中发挥着一定作用。

Objective To investigate the expression of FBXL20 in laryngocarcinoma, analyze the difference of FBXL20 expression in laryngocarcinoma and paracaneerous tissue, discuss the relationship between FBXL20 expression and the pathological and clinical features of laryngocarcinoma,and to explore its potential application value. Methods We detected the expression of FBXL20 in 30 cases of laryngocarcinoma and adjacent non-cancerous tissue by immunohistochemistry. Results FBXL20 expressed in both normal tissues and tumor tissues, mostly concentrating in cytoplasm. The positive rate of FBXL20 expression in normal tis- sues was significantly higher than that in tumor tissues （P = 0. 004）. The expression of FBXL20 significantly correlate with lymphnodes aggression（P = 0. 044）. But the expression of FBXL20 did not tend to correlate with gender, age and the degree of differentia- tion. Conclusion FBXL20 may play an important role in the development of laryngocarcinoma.